Rising SteriLux wins first Australian client

Please login or
register
25.04.2024
Vaud-based SteriLux, a start-up specialized in innovative sterilization systems, is experiencing rapid sales growth. Buoyed by the dynamism of the veterinary market, the company headed by Marc Spaltenstein is winning over new customers in the medical technology sector, such as Nutromics, its first customer in Australia.

Since obtaining its medical certification for the European market in 2021, Vaud-based SteriLux has delivered over 150 sterilization devices, the vast majority (>90%) in the veterinary sector. Designed from the outset as a service for clinics and hospitals concerned with the safety of their operators and patients, SteriLux novel solution first proved its worth with numerous veterinary users.

Today, SteriLux is on a roll. The Renens-based start-up has made a name for itself on the veterinary market with its sustainable solution, which enables medical devices to be sterilized with a minimum of resources and without toxic or carcinogenic chemicals. Over the past year, the Swiss medtech opened 6 new countries and saw the number of devices ordered increase by 68%, making it the market leader in France and Switzerland.

Among its customers, SteriLux works with the prestigious TierSpital in Berne and 11 veterinary clinics in Western Switzerland. Even more impressively, the startup counts as customers 8 of the 13 veterinary hospitals and 2 of the 4 veterinary schools in France.

But the company, which focuses on minimally invasive surgery and reuse markets for single-use devices, also attracts customers from the medtech sector. This is the case, for example, of Nutromics in Australia. The company is developing a wearable device that measures various clinically relevant targets. Founder and CEO Marc Spaltenstein tells us more: "They tested our technology last year and decided to buy one of our devices to continue their tests.

Looking ahead

SteriLux is preparing to enter the North American market in the coming months. The company already has several orders in hand in Canada. Moreover, the CEO tells us that his company intends to increase its recurring revenues by launching a range of flexible endoscopes compatible with its technology.

As far as financing is concerned, Marc Spaltenstein acknowledges that it's currently very difficult to raise funds. Despite this context, SteriLux raised 150k this year to support its growth in line with the strategy defined. In the coming year, SteriLux will continue its growth by focusing in developing new markets and obtain the certificates required for that.

(ES)

0Comments

More news about

SteriLux SA

Company profiles on startup.ch

SteriLux SA

rss